The Future of CRISPR–Cas Systems from Uncultivated Microbes: A BCC Research Special Report

August 15, 2018

WELLESLEY, Mass., Aug15, 2018— CRISPR’s therapeutic promise was recently brought into question when issues, such as immunity to the protein Cas9, were uncovered as major obstacles in moving this genome editing tool to the clinic. CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) technology is among the most important discoveries in life science. As a precise gene editing tool, it has been widely used in many areas with a great potential to treat human diseases.

As such, BCC Research’s report Switching to CRISPR–Cas Systems from Uncultivated Microbes summarizes the major challenges and potential solutions for overcoming preexisting immunity to Cas proteins in humans, such as screening Cas9 enzymes from uncultivated microbes.

Report Includes:

• A detailed overview of the two major types of adaptive immunity to Cas9 proteins, i.e. humoral immunity and cell-mediated immunity
• Comparison of in vivo and ex vivo CRISPR-Cas9 therapy and discussion about clinical safety and probability to enter human clinical trials.
• Coverage of technical areas such as protein engineering and metagenomic analysis as driving forces to new CRISPR-Cas system discovery
• A look into the oncogenic risks by CRISPR-Cas9 genome editing and studies on the development and implementation of genetic systems designed to toggle tumor suppressor genes off and back on again

While many groups are actively resolving obstacles, the significant challenges to minimize the immunological risks and avoid potential tumorgenicity have become big concerns for CRISPR-Cas therapeutics advancing toward the clinic. This report provides a timely summary and analysis of the emerging immunological risk and potential tumorigenicity with the CRISPR-Cas systems to predict how this exciting genome editing market will affect other related segments of the entire life science market in the next few years.

“Ignoring the temporary fluctuations in stock prices of those CRISPR-based therapeutic companies, the scientific community has remained calm. Challenges are just the norm of science – science needs challenges to make breakthroughs.” –Mike Fan, BCC Research Analyst

“This BCC Research Special Report is intended as a way to edit the readers’ knowledge and understanding of this pivotal technology – inserting a short but powerful perspective on what is seriously threatening to de-rail the technical momentum and commercial traction that was built so quickly and ubiquitously.” –Chris Spivey, BCC Research Senior Editor

Editors/reporters requesting analyst interviews should contact Eric Surber at press@bccresearch.com.

Switching to CRISPR-Cas Systems from Uncultivated Microbes( BIO172A )
Publish Date: Aug 2018    

Data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. For media inquiries, email press@bccresearch.com or visit www.bccresearch.com/media to request access to our library of market research.